Skip to content
Godavari Drugs logo

Godavari Drugs

530317 BSE
₹119.35

Close ·

P/E
25.34
View as Markdown
MCP
Close 4 Nov 2026 ₹119.35 +35.74 +42.7% 1Y
Start ₹83.61

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
6.55%
Debt to Equity
1.08
EPS (TTM)
₹4.71
Book Value
₹71.05
Market Cap
—
P/E (TTM)
25.34
P/B
1.68
ROE
6.14%
Dividend Yield
0.00%
EBITDA
₹11.10 Cr
52W High
₹144.35
52W Low
₹69.70

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

46 Average

Data confidence 100/100

Category scores

Quality
46
Average
Returns, margins, earnings quality 22% weight
Valuation
36
Poor
Cheap vs sector & own history 24% weight
Growth
44
Weak
Sales & profit trajectory 9% weight
Financial Health
25
Poor
Solvency, leverage, coverage 9% weight
Momentum
58
Good
Trend strength, vol-adjusted 12% weight
Ownership
51
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

No strengths listed

Weaknesses

6
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -2.91% over past five years.
  • Company has a low return on equity of 9.95% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 150 days.
  • Promoter holding has decreased over last 3 years: -12.9%

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBullish667
OscillatorsBearish261
Moving AveragesStrong Bullish406

Key readings

RSI (14)
46.76
Neutral
MACD (12,26,9)
0.91
Bearish
SMA (50)
116.42
Bullish
SMA (200)
108.65
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+4.09%
5Y−2.93%
3Y−12.82%
1Y−6.19%
TTM+4.76%

Net profit

Net profit growth by window
10Y+14.87%
5Y0.00%
3Y0.00%
1Y0.00%
TTM+9.76%

Operating cash flow

Operating cash flow growth by window
10YTurned positive
5Y0.00%
3Y−57.47%
1Y−90.91%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+3.80 pp
5Y+1.30 pp
3Y+3.18 pp
1Y−1.19 pp
TTM−1.92 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹76.00 Cr
Mar 2018₹64.00 Cr
Mar 2019₹84.00 Cr
Mar 2020₹96.00 Cr
Mar 2021₹123 Cr
Mar 2022₹161 Cr
Mar 2023₹160 Cr
Mar 2024₹157 Cr
Mar 2025₹113 Cr
Mar 2026₹106 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹2.00 Cr
Mar 2018₹1.00 Cr
Mar 2019₹1.00 Cr
Mar 2020₹2.00 Cr
Mar 2021₹4.00 Cr
Mar 2022₹5.00 Cr
Mar 2023₹4.00 Cr
Mar 2024₹6.00 Cr
Mar 2025₹4.00 Cr
Mar 2026₹4.00 Cr

Quarterly Results

₹ Cr
530317 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
35.42
39.54
43.11
38.64
32.21
26.09
29.55
25.5
23.81
26.65
22.18
33.16
27.96
Expenses
33.17
36.47
39.59
34.17
28.98
23.19
26.97
22.39
20.91
24.65
19.71
30.22
25.44
Operating Profit
2.25
3.07
3.52
4.47
3.23
2.9
2.58
3.11
2.9
2
2.47
2.94
2.52
OPM %
6.35%
7.76%
8.17%
11.57%
10.03%
11.12%
8.73%
12.2%
12.18%
7.5%
11.14%
8.87%
9.01%
Other Income
0.45
0
−0.01
0.08
0.77
0.01
0.1
0.11
0.01
0.64
0.27
0.25
0.15
Interest
1.11
1.3
1.27
1.23
1.44
1.08
1.11
1.11
1
0.91
1.11
0.96
0.9
Depreciation
0.47
0.49
0.5
0.53
0.55
0.58
0.64
0.67
0.6
0.6
0.61
0.61
0.59
PBT
1.12
1.28
1.74
2.79
2.01
1.25
0.93
1.44
1.31
1.13
1.02
1.62
1.18
Tax %
27.68%
32.81%
29.89%
4.66%
18.91%
12.8%
16.13%
38.19%
19.85%
10.62%
25.49%
20.37%
5.93%
Net Profit
0.81
0.86
1.22
2.66
1.63
1.09
0.77
0.89
1.04
1
0.76
1.29
1.11
EPS (₹)
1.08
1.14
1.62
3.53
2.16
1.45
1.02
1.18
1.38
1.33
1.01
1.27
1.1

Profit & Loss

₹ Cr
530317 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
55
71
76
64
84
96
123
161
160
157
113
106
110
Expenses
49
67
70
60
78
90
113
150
150
143
102
95
100
Operating Profit
6
4
5
4
5
6
10
11
10
13
12
10
10
OPM %
11%
6%
7%
6%
7%
6%
8%
7%
6%
8%
10%
10%
9%
Other Income
0
0
1
1
0
0
0
0
1
1
1
1
1
Interest
1
2
3
2
3
3
3
3
4
5
5
4
4
Depreciation
1
1
1
1
1
1
1
2
2
2
2
2
2
PBT
5
2
3
1
2
2
6
7
5
7
6
5
5
Tax %
23%
38%
33%
37%
31%
13%
28%
25%
23%
20%
22%
19%
—
Net Profit
4
1
2
1
1
2
4
5
4
6
4
4
4
EPS (₹)
4.85
1.79
2.4
1.1
1.61
2.66
5.48
6.97
5.03
7.37
5.82
4.04
4.71
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
530317 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
8
8
8
8
8
8
8
8
10
Reserves
6
7
9
10
11
13
17
22
26
31
36
66
Borrowings
8
16
16
19
22
28
30
23
36
58
64
82
Other Liabilities
13
21
24
27
33
36
36
49
52
38
35
43
Total Liabilities
35
51
56
63
74
84
91
101
121
135
143
200
Fixed Assets
7
9
13
15
15
14
22
26
25
27
33
30
CWIP
0
1
0
1
2
9
1
0
9
18
30
57
Investments
0
0
0
0
0
0
0
0
0
0
0
0
Other Assets
27
41
43
47
57
61
68
75
87
90
81
114
Total Assets
35
51
56
63
74
84
91
101
121
135
143
200

Cash Flow

₹ Cr
530317 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−6
−5
5
4
4
6
1
11
13
18
11
1
Investing
0
−2
−3
−3
−2
−7
−1
−5
−9
−13
−20
−26
Financing
6
7
−2
0
−1
0
0
−6
−4
−6
8
37
Net Cash Flow
0
0
0
1
0
0
0
1
1
0
0
12
Free Cash Flow
−6
−7
1
0
1
−1
0
6
4
5
−9
−26
CFO/OP
−101
−101
108
109
73
108
26
110
143
146
105
19

Ratios

530317 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
87
126
117
152
148
137
134
126
132
138
136
150
Inventory Days
84
67
70
100
93
84
55
28
57
62
125
217
Days Payable
79
108
124
171
171
144
112
121
132
96
128
163
Cash Conversion Cycle
92
85
63
81
70
78
78
33
58
105
133
204
Working Capital Days
63
44
40
47
38
31
46
32
23
9
11
42
ROCE %
32%
16%
17%
11%
12%
12%
18%
18%
14%
14%
10%
7%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Godavari Drugs insights

68 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 42.96%
  • Promoters 40.23%
  • Others 14.02%
  • DIIs 2.79%

0.21% of promoter holding pledged as of 14 Oct 2026

Change since Jun 2026

Documents

Frequently Asked Questions about Godavari Drugs

What does Godavari Drugs Ltd do?
Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates
Where is Godavari Drugs Ltd (GODAVARI) listed?
Godavari Drugs Ltd trades under code 530317 on the BSE.
Which sector does Godavari Drugs Ltd belong to?
Godavari Drugs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Godavari Drugs Ltd?
Godavari Drugs Ltd trades at a PE ratio of 25.34 as of 4 Nov 2026, on earnings per share of ₹4.71, against a book value of ₹71.05 per share.
What is the 52-week high and low of Godavari Drugs Ltd?
Over the last 52 weeks Godavari Drugs Ltd has traded between ₹69.7 and ₹144.35 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Godavari Drugs Ltd?
Godavari Drugs Ltd reported a return on equity of 6.14%. Its debt-to-equity ratio is 1.08.

Company Information

Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates

Website godavaridrugs.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530317.md for Godavari Drugs Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month